Show simple item record

dc.contributor.authorGuglielmetti, L
dc.contributor.authorLow, M
dc.contributor.authorMcKenna, L
dc.date.accessioned2020-06-23T18:37:59Z
dc.date.available2020-06-23T18:37:59Z
dc.date.issued2020-04-28
dc.date.submitted2020-05-28
dc.identifier.pmid32345064
dc.identifier.doi10.1080/14787210.2020.1756776
dc.identifier.urihttp://hdl.handle.net/10144/619631
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.rightsWith thanks to Taylor & Francis.en_US
dc.subjectEMA
dc.subjectFDA
dc.subjectMDR-TB
dc.subjectTuberculosis
dc.subjectWHO
dc.subjectXDR-TB
dc.subjectclinical trial
dc.subjectdrug resistance
dc.subjectnew drug
dc.titleChallenges in TB regimen development: preserving evidentiary standards for regulatory decisions and policymakingen_US
dc.typeOther
dc.identifier.eissn1744-8336
dc.identifier.journalExpert Review of Anti-infective Therapyen_US
dc.source.journaltitleExpert review of anti-infective therapy
dc.source.beginpage1
dc.source.endpage3
refterms.dateFOA2020-06-23T18:38:00Z
dc.source.countryEngland


Files in this item

Thumbnail
Name:
Guglielmetti et al 2020 Challenges ...
Size:
578.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record